Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f orward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... raffle. Throughout the month of February, patients who visit Hamlin Dental Group will receive ... dinner for two at the Cheesecake Factory. , Tickets are available for routine ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig ... where generations converge and explore the world from different perspectives. By providing a ... readers to gain understanding, increase empathy, and find greater happiness. , "Our ...
(Date:2/23/2017)... ... ... perfect opportunity for the nation to come together to combine ... bracket – with its favorite fruit – apples! To celebrate ... lovers to join the “Apple Madness” bracket tournament – a ...
Breaking Medicine News(10 mins):